For refractory/relapsed AML patients with isocitrate dehydrogenase (IDH) 1/2 mutation, IDH1 inhibitors, such as ivosidenib, and IDH2 inhibitors, such as enasidenib, have presented well-tolerated outcomes in clinical trials (49, 50). This evidence concerns the gene IDH1 and acute myeloid leukemia.